Trial · NCT07909070
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PK parameter Cmax | Predose up to 6 days postdose | maximum observed plasma concentration |
| Primary | PK parameters AUC0-t | Predose up to 6 days postdose | area under the curve from time zero to the specified time point |
| Primary | PK parameters AUC0-inf | Predose up to 6 days postdose | area under the curve from time Zero extrapolated to Infinity |
| Primary | PK parameters Cmax, u | Predose up to 6 days postdose | unbound maximum plasma concentration |
| Primary | PK parameters AUC0-t, u | Predose up to 6 days postdose | area under the unbound concentration-time curve from time zero to the specified time point |
| Primary | PK parameters AUC0-inf, u | Predose up to 6 days postdose | area under the unbound concentration-time curve curve from time Zero extrapolated to Infinity |
| Secondary | PK parameters tmax | Predose up to 6 days postdose | time to reach maximum observed plasma concentration |
| Secondary | PK Parameters t1/2 | Predose up to 6 days postdose | terminal phase half-life |
| Secondary | PK Parameters Vz/F | Predose up to 6 days postdose | apparent volume of distribution |
| Secondary | PK Parameters CL/F | Predose up to 6 days postdose | apparent clearance |
| Secondary | plasma protein binding (PPB) and fraction unbound (fu) | Predose up to 6 days postdose | plasma protein binding rate |
| Secondary | PK Parameters CL/F, u | Predose up to 6 days postdose | unbound apparent clearance |
| Secondary | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | up to 14 days postdose | To evaluate the safety and tolerability of a single dose of JMKX003142 in subjects with mild or moderate hepatic impairment, and in healthy subjects with normal hepatic function |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07909070/registered